Thrombopoietin Receptor Agonists in Primary Immune Thrombocytopenia

Seminars in Hematology

Volumn 50, Issue SUPPL.1, 2013, Pages

  Siegal, Deborah ^a   Crowther, Mark ^a   Cuker, Adam ^b,c  

^a MCMASTER UNIVERSITY   (Canada)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; CYTOKINE RECEPTOR AGONIST; ELTROMBOPAG; PLACEBO; ROMIPLOSTIM; THROMBOPOIETIN; THROMBOPOIETIN RECEPTOR; THROMBOPOIETIN RECEPTOR STIMULATING AGENT; UNCLASSIFIED DRUG;

ARTHRALGIA; ARTICLE; AUTOIMMUNE THROMBOCYTOPENIA; BLEEDING; DOSE RESPONSE; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; HUMAN; HYPERBILIRUBINEMIA; MEGAKARYOCYTE; MYELOFIBROSIS; NAUSEA; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; REPEATED DRUG DOSE; RHINOPHARYNGITIS; SIDE EFFECT; SINGLE DRUG DOSE; THROMBOCYTE COUNT; THROMBOCYTOPOIESIS; THROMBOEMBOLISM; THROMBOSIS;

BENZOATES; CLINICAL TRIALS, PHASE III AS TOPIC; HUMANS; HYDRAZINES; PYRAZOLES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTORS, FC; RECEPTORS, THROMBOPOIETIN; RECOMBINANT FUSION PROTEINS; THROMBOCYTOPENIA; THROMBOPOIESIS; THROMBOPOIETIN;

EID: 84877661612     PISSN: 00371963     EISSN: 15328686     Source Type: Journal    
DOI: 10.1053/j.seminhematol.2013.03.005     Document Type: Article

References (33)

1. Neunert C., Lim W., Crowther M., Cohen A., Solberg L., Crowther M.A. The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia. Blood 2011, 117(16):4190-4207.
2. Aledort L.M., Hayward C.P., Chen M.G., Nichol J.L., Bussel J. Prospective screening of 205 patients with ITP, including diagnosis, serological markers, and the relationship between platelet counts, endogenous thrombopoietin, and circulating antithrombopoietin antibodies. Am J Hematol 2004, 76:205-213.
3. Kaushansky K. The molecular mechanisms that control thrombopoiesis. J Clin Invest 2005, 115(12):3339-3347.
4. Stasi R., Bosworth J., Rhodes E., Shannon M.S., Willis F., Gordon-Smith E.C. Thrombopoietic agents. Blood Rev 2010, 24(4-5):179-190.
5. Fanucchi M., Glaspy J., Crawford J., et al. Effects of polyethylene glycol-conjugated recombinant human megakaryocyte growth and development factor on platelet counts after chemotherapy for lung cancer. N Engl J Med 1997, 336(6):404-409.
6. Kuter D.J., Begley C.G. Recombinant human thrombopoietin: basic biology and evaluation of clinical studies. Blood 2002, 100(10):3457-3469.
7. Li J., Yang C., Xia Y., et al. Thrombocytopenia caused by the development of antibodies to thrombopoietin. Blood 2001, 98(12):3241-3248.
8. Wang B., Nichol J.L., Sullivan J.T. Pharmacodynamics and pharmacokinetics of AMG 531, a novel thrombopoietin receptor ligand. Clin Pharmacol Ther 2004, 76(6):628-638.
9. Imbach P., Crowther M. Thrombopoietin-receptor agonists for primary immune thrombocytopenia. N Engl J Med 2011, 365(8):734-741.
10. Kuter D.J., Bussel J.B., Lyons R.M., et al. Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial. Lancet 2008, 371(9610):395-403.
11. George J.N., Mathias S.D., Go R.S., et al. Improved quality of life for romiplostim-treated patients with chronic immune thrombocytopenic purpura: results from two randomized, placebo-controlled trials. Br J Haematol 2009, 144(3):409-415.
12. Kuter D.J., Mathias S.D., Rummel M., et al. Health-related quality of life in nonsplenectomized immune thrombocytopenia patients receiving romiplostim or medical standard of care. Am J Hematol 2012, 87(5):558-561.
13. Michel M., te Boekhorst P.A., Janssens A., et al. Reduced corticosteroid use in adult patients with primary immune thrombocytopenia receiving romiplostim. Hematology 2011, 16(5):274-277.
14. Kuter D.J., Bussel J.B., Newland A., et al. Long-term efficacy and safety of romiplostim treatment of adult patients with chronic immune thrombocytopenia (ITP): final report from an open-label extension study. ASH Annual Meeting Abstracts 2010, 116(21):68.
15. Kuter D.J., Rummel M., Boccia R., et al. Romiplostim or standard of care in patients with immune thrombocytopenia. N Engl J Med 2010, 363(20):1889-1899.
16. Khellaf M., Michel M., Quittet P., et al. Romiplostim safety and efficacy for immune thrombocytopenia in clinical practice: 2-year results of 72 adults in a romiplostim compassionate-use program. Blood 2011, 118(16):4338-4345.
17. Erickson-Miller C.L., Delorme E., Tian S.S., et al. Preclinical activity of eltrombopag (SB-497115), an oral, nonpeptide thrombopoietin receptor agonist. Stem Cells 2009, 27(2):424-430.
18. Erickson-Miller C.L., DeLorme E., Tian S.S., et al. Discovery and characterization of a selective, nonpeptidyl thrombopoietin receptor agonist. Exp Hematol 2005, 33(1):85-93.
19. Jenkins J.M., Williams D., Deng Y., et al. Phase 1 clinical study of eltrombopag, an oral, nonpeptide thrombopoietin receptor agonist. Blood 2007, 109(11):4739-4741.
20. Bussel J.B., Cheng G., Saleh M.N., et al. Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura. N Engl J Med 2007, 357(22):2237-2247.
21. Bussel J.B., Provan D., Shamsi T., et al. Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: a randomised, double-blind, placebo-controlled trial. Lancet 2009, 373(9664):641-648.
22. Cheng G., Saleh M.N, Marcher C, et al. Eltrombopag for management of chronic immune thrombocytopenia (RAISE): a 6-month, randomised, phase 3 study. Lancet 2011, 377(9763):393-402.
23. Nplate (romiplostim) prescribing information. (Accessed at on Apr 25, 2012. http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/125268s077lbl.pdf.
24. Promacta (eltrombopag) prescribing information. (Accessed at on Apr 25, 2012. http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022291s006lbl.pdf.
25. Bussel J.B., Kuter D.J., Pullarkat V., Lyons R.M., Guo M., Nichol J.L. Safety and efficacy of long-term treatment with romiplostim in thrombocytopenic patients with chronic ITP. Blood 2009, 113(10):2161-2171.
26. Gernsheimer T.B., George J.N., Aledort L.M., et al. Evaluation of bleeding and thrombotic events during long-term use of romiplostim in patients with chronic immune thrombocytopenia (ITP). J Thromb Haemost 2010, 8(6):1372-1382.
27. Saleh M.N., Cheng G., Bussel J.B., et al. EXTEND study update: safety and efficacy of eltrombopag in adults with chronic immune thrombocytopenia (ITP) from June 2006 to February 2010. ASH Annual Meeting Abstracts 2010, 116(21):67.
28. Leung T., Lokan J., Turner P., Smith C. Reversible bone marrow reticulin fibrosis as a side effect of romiplostim therapy for the treatment of chronic refractory immune thrombocytopenia. Pathology 2011, 43(5):520-522.
29. Ghanima W., Junker P., Hasselbalch H.C., et al. Fibroproliferative activity in patients with immune thrombocytopenia (ITP) treated with thrombopoietic agents. Br J Haematol 2011, 155(2):248-255.
30. Kuter D.J., Mufti G.J., Bain B.J., Hasserjian R.P., Davis W., Rutstein M. Evaluation of bone marrow reticulin formation in chronic immune thrombocytopenia patients treated with romiplostim. Blood 2009, 114(18):3748-3756.
31. Brynes R.K., Orazi A., Verma S., Brainsky A., Bailey C.K., Bakshi K. Evaluation of bone marrow reticulin in patients with chronic immune thrombocytopenic purpura (ITP) treated with eltrombopag-data from the EXTEND study. ASH Annual Meeting Abstracts 2011, 118(21):528.
32. Provan D., Stasi R., Newland A.C., et al. International consensus report on the investigation and management of primary immune thrombocytopenia. Blood 2010, 115(2):168-186.
33. Lakshmanan S., Cuker A. Contemporary management of primary immune thrombocytopenia in adults. J Thromb Haemost 2012, 10(10):1988-1998.